Get access

CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma

Authors

  • R. B. Rebhun,

    Corresponding author
    1. Department of Surgical and Radiological Sciences and The Comparative Cancer Center, One Shields Avenue, University of California, Davis, CA, USA
    Search for more papers by this author
  • M. S. Kent,

    1. Department of Surgical and Radiological Sciences and The Comparative Cancer Center, One Shields Avenue, University of California, Davis, CA, USA
    Search for more papers by this author
  • S. A. E. B. Borrofka,

    1. Department of Surgical and Radiological Sciences and The Comparative Cancer Center, One Shields Avenue, University of California, Davis, CA, USA
    Search for more papers by this author
    • Current address: University Clinic for Companion Animals, Division of Diagnostic Imaging, Yalelaan108, 3584 CM Utrecht, The Netherlands.

  • S. Frazier,

    1. Department of Surgical and Radiological Sciences and The Comparative Cancer Center, One Shields Avenue, University of California, Davis, CA, USA
    Search for more papers by this author
  • K. Skorupski,

    1. Department of Surgical and Radiological Sciences and The Comparative Cancer Center, One Shields Avenue, University of California, Davis, CA, USA
    Search for more papers by this author
  • C. O. Rodriguez

    1. Department of Surgical and Radiological Sciences and The Comparative Cancer Center, One Shields Avenue, University of California, Davis, CA, USA
    Search for more papers by this author

R. B. Rebhun
Department of Surgical and Radiological Sciences and The Comparative Cancer Center
2112 Tupper Hall
One Shields Avenue
University of California
Davis, CA 95616
USA
e-mail: rbrebhun@ucdavis.edu

Abstract

Dogs with multicentric T-cell lymphoma are commonly treated with CHOP chemotherapy protocols that include cyclophosphamide, doxorubicin, vincristine and prednisone. The purpose of this study was to evaluate the use of CHOP chemotherapy for dogs with multicentric T-cell lymphoma. Identification of prognostic factors in this specific subset of dogs was of secondary interest. Twenty-three out of 24 dogs responded to CHOP chemotherapy and these dogs remained on the protocol for a median of 146 days. No variable was associated with progression free survival (PFS) including stage, substage, hypercalcemia or radiographic evidence of a cranial mediastinal mass. The median overall survival time (OST) for all dogs was 235 days. Dogs that were thrombocytopenic at presentation experienced a significantly longer OST (323 versus 212 days, P = 0.01).

Ancillary